Journal Information
Vol. 41. Issue. 5.September - October 2021
Pages 489-604
Vol. 41. Issue. 5.September - October 2021
Pages 489-604
Letter to the Editor
Open Access
Ischaemic stroke associated with COVID-19 in dialysis patients
Ictus isquémico asociado a COVID-19 en pacientes en diálisis
Alberto de Lorenzoa,
Corresponding author
, Laura Espinela, Ángela Revillab, Teresa Corbalánc, Judith Martinsa, María Teresa Nayaa, Alfonso Cubasa
a Servicio de Nefrología, Hospital Universitario de Getafe, Getafe, Madrid, Spain
b Centro de Salud El Greco, Getafe, Madrid, Spain
c Servicio de Radiodiagnóstico, Hospital Universitario de Getafe, Getafe, Madrid, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Download PDF
Figures (1)
Tables (1)
Table 1. Demographic, laboratory and clinical data.
Full Text
Dear Editor,

Since December 2019, when the first cases were reported in China until now the novel SARS-CoV-2 coronavirus has caused the death of more than 1,000,000 people around the world. In addition to the, already known, manifestations associated with the infection, other less common signs and symptoms are emerging that are important due to the potentially fatal nature.1,2 We report three patients with chronic kidney disease (CKD) on renal replacement therapy (RRT) who suffered a stroke in relation to a COVID-19 infection. Between 10 March and 25 April 2020, 16 patients on RRT (one on peritoneal dialysis [PD]) positive for SARS-CoV-2 were admitted to our department. Of the 16 patients, 3 (18.7%) suffered a stroke and one of them died.

Patient 1: 85-year-old man with CKD secondary to nephroangiosclerosis, on RRT since 2014 (initially on PD and since 2017 on haemodialysis [HD]).The patient had hypertension, non-ischaemic dilated cardiomyopathy and severe chronic obstructive pulmonary disease and had suffered an atherothrombotic stroke two weeks earlier. He was admitted for moderate unilateral pneumonia due to SARS-CoV-2 and received hydroxychloroquine and lopinavir/ritonavir according to protocol. On the sixth day of admission, while following a suitable respiratory clinical course, he presented an episode of right hemiparesia and reduced consciousness from which he recovered hours later. Given his prior atherothrombotic stroke with the same signs and symptoms, the same location was assumed, and given that the patient was a candidate for conservative treatment with antiplatelet therapy only (which he was already receiving), imaging test was no repeated. On the eighth day, prior to the dialysis session, he presented an identical episode; respiratory impairment was observed and laboratory testing revealed significantly increased C-reactive protein (CRP) levels, worsening of lymphopenia and elevated D-dimer levels. The patient did not recover and died within 24h. We believe that his first cerebrovascular accident may have been his initial presentation of COVID-19 two weeks before his pneumonia; this would be in line with other published series.3–5

Patient 2: A 71-year-old man with CKD secondary to chronic interstitial nephropathy due to obstructive uropathy caused by urothelial bladder carcinoma. He had been on HD since 2015 and had experienced multiple problems with vascular access. At the time of his admission, he had a femoral Permcath. He had hypertension, squamous cell lung carcinoma and moderate to severe left ventricular dysfunction. He was admitted for diarrhoea, fever and mild bilateral pneumonia due to SARS-CoV-2. He received hydroxychloroquine for five days and lopinavir/ritonavir for seven days. He had a favourable clinical and laboratory course, except for a gradual increase in D-dimer up to six fold after the conclusion of the immunomodulatory therapy on the ninth day of admission. Hence, due to the high risk of thrombosis and according to protocol, we started heparin at 1mg/kg/day. Few days later, the patient was discharged and was kept on heparin for two more weeks. Two weeks after heparin was suspended, he was admitted due to a sensory deficit of the left side of the body. As shown in Fig. 1 it was observed a right thalamic lacunar subacute stroke with no evidence of potentially embolic heart disease or carotid atheromatosis (Fig. 1). Antiplatelet therapy was added, and 11 days later, he was readmitted due to a second stroke, this time in the region of the left middle cerebral artery, with aphasia without a recovery. At the time of this writing, he remains in hospital.

Figure 1.

Neuroradiology imaging. A) MRI of patient 2. Hyperintense lesion on T2-weighted sequences located in lateral nuclei of the thalamus/posterior limb of the right internal capsule, consistent with lacunar infarction. B) MRI of patient 2. Restricted diffusion sequence imaging confirming stroke from prior image with an acute/subacute course. C) CT scan of patient 2. Cortical/subcortical hypodensity in the left temporal region consistent with ischaemic lesion. D) MRI of patient 3. Hyperintense lesion on T2-weighted sequences located in the cerebellar vermis consistent with infarction. E) MRI of patient 3. Diffusion-weighted imaging identifying a focus of signal abnormality in the cerebellar vermis, which restricts on an apparent diffusion coefficient (ADC) map, consistent with acute/subacute infarction in the location reported on T2-weighted imaging in the prior image.


Patient 3: An 80-year-old man with a single functional kidney due to ischaemia that had been on PD since 2015. He suffered from grade 2A chronic ischaemia of both legs and had undergone a carotid endarterectomy in 2011. He was admitted for moderate bilateral pneumonia due to SARS-CoV-2 and treated with hydroxychloroquine for five days and lopinavir/ritonavir for seven days. He progressed favourably and was discharged two weeks after admission; prophylactic heparin was continued for another 10 days. Twenty-four hours after discharge, he presented a rash with papular erythematous lesions on his trunk that mostly spared his legs and spared his arms entirely. He was assessed by dermatology, which, after biopsy, diagnosed him with exanthema probably secondary to COVID-19. After two weeks of antithrombotic prophylaxis, heparin was suspended. Five days later, the patient developed monoparesis of the right leg of sudden onset. He was admitted to Neurology, and magnetic resonance imaging revealed an acute infarction in the cerebellar vermix (Fig. 1). An ultrasound showed no evidence of embolic heart disease, and a neurosonology study found no evidence of intracranial or extracranial stenosis. The patient recovered mobility, remained asymptomatic, and he was discharged (Table 1).

Table 1.

Demographic, laboratory and clinical data.

  Patient 1  Patient 2  Patient 3 
Age (years)  85  71  80 
HTN  Yes  Yes  Yes 
DM  No  No  No 
DL  No  No  No 
Ischaemic cardiopathy  No  No  No 
Peripheral arteriopathy  Yes  No  Yes 
Prior CVA  Yes  No  No 
Atrial fibrillation  No  No  No 
Artificial valve  No  No  No 
Prior anticoagulation  No  No  No 
Prior kidney transplant  No  No  No 
Time on renal replacement therapy (years)  5.3  4.4  4.4 
Renal replacement therapy type  HD  HD  PD 
Venous access  AVF  Permanent catheter  N/A 
EPO (IU/week)  2000  15,000  6000 
ASA  Yes  Yes  Yes 
Pneumonia  Moderate unilateral  Mild bilateral  Moderate bilateral 
Days of admission  12  15 
ICU admission  No  No  No 
Immunomodulatory therapy  Hydroxychloroquine, lopinavir/ritonavir  Hydroxychloroquine, lopinavir/ritonavir  Hydroxychloroquine, lopinavir/ritonavir 
Duration of immunomodulatory therapy (days)  5+5+
Treatment with steroids  No  No  No 
Prophylactic heparin on admission (mg/24h)  20  20  20 
High risk of thrombosis (D-dimer >6 times monitoring level)  No  Yes (day 9)  No 
Dose of heparin due to high risk of thrombosis (mg/day)  N/A  60  N/A 
Duration of intermediate dose heparin treatment (days)  18 
Total heparin treatment duration (days)  27  25 
CRP (mg/l) on admission/maximum (ref. 0.0−0.5)  87.1/216  85.7/116.1  15.9/103.4 
Ferritin (μg/l) on admission/maximum (ref. 30.0–400.0)  NA  454/502  236/328 
LDH (U/l) on admission/maximum (ref. 135−225)  228/249  229/313  160/194 
Hb (g/dl) on admission (ref. 13.0−17.5)  12  10.9  10.8 
Platelets (103/μl) on admission (ref. 150−450)  222  130  134 
Lymphopenia (103/μl) on admission/maximum (ref. 1.00−4.50)  520/180  1007/780  1222/760 
D-dimer (mg/l) on admission/maximum (ref. <0.5)  3.2/3.2  2.1/5.3  1.11/1.11 
Fibrinogen (mg/dl) on admission/maximum (ref. 200.0−400.0)  NA  536/565  456/956 
Time from onset of symptoms to CVA (days)  16  40  31 
Time from SARS-CoV-2 diagnosis to CVA (days)  38/52  30 
Time from virus CRP becoming negative to CVA (days)  N/A  17/31  16 
Time from end of heparin to CVA (days)  N/A  15/29 
CVA type  Ischaemic  Ischaemic/ischaemic  Ischaemic 
Location  M2 branch of left MCA  Right thalamic lacunar/left MCA  Cerebellar vermis 
Other late signs of COVID-19  No  No  Exanthema 
Death  Yes  No  No 

5+7: five days of hydroxychloroquine and seven days of lopinavir/ritonavir; ASA: acetylsalicylic acid; AVF: arteriovenous fistula; CRP: C-reactive protein; CVA: cerebrovascular accident; DL: dyslipidaemia; DM: diabetes mellitus; EPO: erythropoietin; HD: haemodialysis; HTN: arterial hypertension; ICU: intensive care unit; LDH: lactate dehydrogenase; MCA: middle cerebral artery; N/A: not applicable; NA: not available; PD: peritoneal dialysis; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

Although the specific incidence of stroke in patients with COVID-19 is unknown, the literature on this subject is growing exponentially.1 According to Mao et al.,6 in a cohort of 214 patients admitted for SARS-CoV-2, 5.7% presented stroke (in the final stage of the infection). Li et al.7 recently published an incidence of 5% (in early stages of the infection) in patients with risk factors such as hypertension, diabetes, coronary disease and stroke. A series by Beyrouti et al.4 reported six cases of stroke with moderate to severe COVID-19 that presented between day 0 and day 24 after the onset of symptoms. Lodigiani et al.8 compiled a cohort of 388 patients hospitalised due to SARS-CoV-2 and found an incidence of ischaemic stroke of 2.5%. Although the pathophysiological mechanisms are not clear,4 the factors that appear to be involved are: hypoxia, an hypercoagulable state,3 disseminated intravascular coagulation, thrombotic microangiopathy and occasional positivity for anticardiolipin antibodies and lupus anticoagulant appear.9,10 There are no references in the literature in the dialysis population, which means that this is the first publication to address this matter; the findings point to a probable higher incidence than in the general population.

D.C. Hess, W. Eldahshan, E. Rutkowski.
COVID-19-related stroke.
Transl Stroke Res, 11 (2020), pp. 322-325
G. Aggarwal, G. Lippi, B. Michael Henry.
Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): a pooled analysis of published literature.
A. Avula, K. Nalleballe, N. Narula, S. Sapozhnikov, V. Dandu, S. Toom, A. Glaser, et al.
COVID-19 presenting as stroke.
R. Beyrouti, M.E. Adams, L. Benjamin, H. Cohen, S.F. Farmer, Y.Y. Goh, et al.
Characteristics of ischaemic stroke associated with COVID-19.
J Neurol Neurosurg Psychiatry, (2020),
T.J. Oxley, J. Mocco, S. Majidi, C.P. Kellner, H. Shoirah, I.P. Singh, et al.
Large-vessel stroke as a presenting feature of Covid-19 in the young.
L. Mao, H. Jin, M. Wang, Y. Hu, S. Chen, Q. He, et al.
Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China.
JAMA Neurol, 10 (2020), pp. e201127
Li Y, Wang M, Zhou Y, Chang J. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. [Accessed 2 May 2020]. Available from:
C. Lodigiani, G. Iapichino, L. Carenzo, M. Cecconi, P. Ferrazzi, T. Sebastian, et al.
Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.
N. Tang, H. Bai, X. Chen, J. Gong, D. Li, Z. Sun.
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.
J Thromb Haemost, 18 (2020), pp. 1094-1099
T. Iba, J.H. Levy, T.E. Warkentin, J. Thachil, T. van der Poll, M. Levi.
Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation.
J Thromb Haemost, 17 (2019), pp. 1989-1994

Please cite this article as: de Lorenzo A, Espinel L, Revilla A, Corbalán T, Martins J, Naya MT, et al. Ictus isquémico asociado a COVID-19 en pacientes en diálisis. Nefrologia. 2021;41:590–593.

Copyright © 2020. Sociedad Española de Nefrología
Nefrología (English Edition)
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?